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Abstract
Currently the study of Regulated Cell Death (RCD) processes is limited to the use of lysed cell populations for Western 
blot analysis of each separate RCD process. We have previously shown that intracellular antigen flow cytometric analysis of 
RIP3, Caspase-3 and cell viability dye allowed the determination of levels of apoptosis (Caspase-3+ ve/RIP3− ve), necroptosis 
 (RIP3Hi + ve/Caspase-3− ve) and RIP1-dependent apoptosis (Caspase-3+ ve/RIP3+ ve) in a single Jurkat cell population. The addi-
tion of more intracellular markers allows the determination of the incidence of parthanatos (PARP), DNA Damage Response 
(DDR, H2AX), H2AX hyper-activation of PARP (H2AX/PARP) autophagy (LC3B) and ER stress (PERK), thus allowing 
the identification of 124 sub-populations both within live and dead cell populations. Shikonin simultaneously induced Jurkat 
cell apoptosis and necroptosis the degree of which can be shown flow cytometrically together with the effects of blockade of 
these forms of cell death by zVAD and necrostatin-1 have on specific RCD populations including necroptosis, early and late 
apoptosis and RIP1-dependent apoptosis phenotypes in live and dead cells. Necrostatin-1 and zVAD was shown to modulate 
levels of shikonin induced DDR, hyper-action of PARP and parthanatos in the four forms of RCD processes analysed. LC3B 
was up-regulated by combined treatment of zVAD with chloroquine which also revealed that DNA damage was reduced 
in live cells but enhanced in dead cells indicating the role of autophagy in maintaining cell health. This approach to RCD 
research should be a great advance to understanding the mechanisms of drugs and their effects upon RCD populations.
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Abbreviations
CALR  Calreticulin
CQ  Choloroquine
DDR  DNA damage response
DN  Double negative
ER  Endoplasmic reticulum
HA2X  Histone A2 family X
Hyper-act PARP  Hyper-activation PARP
LC3B  Microtubule associated light chain B
MFI  Median fluorescence intensity
MPT  Mitochondrial permeability transition 
pore complex
Nec-1  Necrostatin-1
PARP  Poly (ADP-ribose) polymerase 1
PERK  protein kinase R-like endoplasmic 
reticulum kinase
QN  Quadruple negative
RCD  Regulated cell death
RIP1  Receptor-interacting serine/threonine-
protein kinase 1
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RIP1 APO  RIP1-dependent apoptosis
RIP3  Receptor-interacting serine/threonine-
protein kinase 3
RT  Room temperature
zVAD  Carbobenzoxy-valyl-alanyl-aspar-
tyl-[O-methyl]-fluoromethyl ketone
Introduction
The evolution of the cell death classification from sim-
ple macroscopic morphological characteristics termed 
Type I–III modes of cell death, including apoptosis, 
autophagy and necrosis, respectively to now include bio-
chemical and functional parameters has refined and reclas-
sified the many forms of Regulated Cell Death (RCD) 
[1–4]. These include intrinsic and extrinsic apoptosis (often 
expressing active caspase-3), immunogenic cell death (ICD) 
or viral-infection induced translocation of calreticulin 
(CALR) from the ER to the outer plasma membrane leaf-
let [5], autophagy (up-regulation of LC3B) and lysosome 
dependent cell death (caused by cathepsins) [4], necroptosis 
(up-regulation of RIP3) [6], MPT or mitochondrial “perme-
ability transition pore complex”—driven necrosis (Oxidative 
stress and calcium overload) [4], parthanatos (hyper-activa-
tion of Poly (ADP-ribose) polymerase or PARP) caused by 
excessive DNA damage (e.g. by H2AX) [7–9], pyroptosis 
(up-regulation of Caspase-1 and plasma membrane pre-for-
mation by gasdermin) [10], ferroptosis which is ROS and 
iron dependent lipid peroxidation and mitochondrial dys-
function controlled by GPX4 or GSH-dependent enzyme 
glutathione peroxidase [11], NETotic cell death (granulocyte 
H2AX) and entotic cell death or loss of integrin signalling 
in epithelial cells [4]. This classification currently leaves out 
RIP1-dependent apoptosis RIP3/Caspase-3 [6, 12–14], the 
DNA Damage Response (DDR) [15] and ER stress, which 
causes autophagy and apoptotic cell death [4, 16], with cell 
senescence [17] and mitotic catastrophe being classed as a 
non-lethal process [18].
Determination of the type of RCD prevalent in a cell 
sample is currently determined by Western blot analysis of 
a lysed cell population and use of the antibody against a 
specific intracellular target antigen such as Caspase-3, RIP1, 
RIP3, LC3B, HA2X or PARP to determine which RCD is 
predominately present and to what degree. The recent [19] 
development of a three colour flow cytometry assay in this 
laboratory targeting Caspase-3, RIP3 and cell viability has 
allowed the detection and quantification of multiple forms 
of RCD including, necroptosis, early and late apoptosis and 
RIP1-dependent apoptosis simultaneously in a single cell 
population.
The addition of PARP and H2AX to identify parthanatos, 
DDR and H2AX hyper-activation of PARP in live and dead 
cells allows the detection of 24 distinct populations [19] and 
demonstrated that double negative (DN) cells for RIP3 and 
caspase-3 undergo mainly parthanatos [19].
In this study we have added markers for autophagy 
(LC3B) and ER stress (PERK) making it possible to detect 
248 RCD Jurkat cell populations flow cytometrically [4, 
20–22]. This multiplexing was particularly useful for inves-
tigating the mode of action of drugs. For example the drug 
shikonin a naturally occurring naphthoquinone which [19, 
23–26] is known to induce apoptosis as well as necropto-
sis in Jurkat cells, so we investigated the modulation of the 
incidence of these and other types of RCD including RIP1-
dependent apoptosis, DDR, hyper-action of PARP and part-
hanatos by pan-caspase and RIP protein blocker zVAD and 
necrostatin-1 respectively [26, 27]. Extending the protocol 
to include analysis of autophagy was investigated how this 
form of RCD maintains cell health by measurement of the 
incidence of DNA damage in live and dead autophagic Jur-
kat cells [28]. Other cell types not included in this study 
were also analysed giving similar distribution of the mark-
ers employed in this study, these included K562 (myeloid 
leukemic cell), NTERT keratinocytes and hepatocyte cell 
line Huh7.5-SEC14L2.
Materials and methods
Cell cultures
Jurkat cells (human acute T cell leukaemia cell line) were 
grown in RPMI 1640 medium with 10% FBS (Invitrogen, 
UK) at 37 °C with 5%  CO2 either untreated or treated with 
shikonin (0.5 µM, Santa Cruz, USA) or chloroquine (CQ, 
100 µM, Sigma Chemicals, UK) for 24 h. Cells were also 
pre-treated with pan-caspase blocker zVAD (20 µM, Enzo 
Life Sciences, USA) and/or necroptosis blocker necrosta-
tin-1 (60 µM Cambridge Bioscience, UK) for 2 h before 
drug treatment.
Flow cytometry analysis
Harvested Jurkat cells were labelled with fixable live dead 
stain, Zombie NIR (Near Infra-Red) (BioLegend, UK) at 
RT for 15 min. Washed cell pellets were fixed in Solution A 
(CalTag, UK) for 15 min at RT. Washed cells were then per-
meabilised in 0.25% Triton X-100 (Sigma, UK) for 15 min at 
RT. Cells (1 × 106) were subsequently incubated for 20 min 
at RT with anti-LC3B monoclonal antibody (1:400 dilu-
tion, Cat No 3868, Cell Signalling Technology Inc., US). 
Washed cells were then labelled with 0.125 µg of secondary 
fluorescent conjugate Alexa Fluor 647 donkey anti-rabbit 
IgG (Invitrogen, UK). Washed cells (0.5 × 106) were then 
labelled 2 µl of anti-PERK-AF488, RIP3-PE (clone B-2, 
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Cat. No. sc-374639, Santa Cruz, USA), PARP-PE-CF-595 
(Becton Dickinson, UK), H2AX-PE-Cy7 (BioLegend, UK) 
and anti-active caspase-3-BV650 (Becton Dickinson, UK) 
for 20 min at RT. Washed cells were resuspended in 400 µl 
PBS and analysed on a ACEA Bioscience Novocyte 3000 
flow cytometer (100,000 events).
RCD phenotype strategy
Cells were gated on FSC vs. SSC removing the small 
debris near the origin with single cells being gated on 
a FSC-A vs. FSC-H dot-plot. Cells were then gated on 
a dot-plot of Caspase-3-BV650 vs. Zombie NIR with a 
quadrant placed with live cells in the double negative 
quadrant (lower left), with Caspase-3-BV650+ ve/Zom-
bie  NIR− ve (lower right) indicating early apoptotic cells, 
with late apoptotic and necrotic cells gated to include 
Caspase-3-BV650+ ve/Zombie  NIR+ ve and Caspase-
3-BV650− ve/Zombie  NIR+ ve (see Fig. 1a). Live (including 
early apoptotic) and dead cells were gated separately and 
analysed in RIP3 vs. Caspase-3 dot-plots with  RIP3+ ve/
Caspase-3− ve indicating normal resting cells or necroptosis 
when RIP3 Median Fluorescence Intensity (MFI) was up-
regulated.  RIP3− ve/Caspase-3+ ve cells indicate those that 
have undergone apoptosis. Double positive events indicate 
cells of the RIP1-dependent apoptosis phenotype (Fig. 1b, 
c). This is an assumed observation, as RIP3 is associated 
with RIP1 in the formation of the necrosome (RIP1 and 
RIP3 were observed to be present in PBMNC, data not 
shown [23]). For each of these phenotypes the incidence 
of DDR  (H2AX+ ve/PARP− ve), H2AX hyper-activation 
of PARP  (H2AX+ ve/PARP+ ve), parthanatos  (H2AX− ve/
PARP+ ve) and quadruple negative (QN) populations were 
determined (Fig. 1d, e).
Fig. 1  Schematic of immunophenotyping of RCD. Live (including 
early apoptotic) and dead (including late apoptotic) cells were gated 
from a Zombie NIR vs. Caspase-3-BV650 dot-plot (a). Live and dead 
necroptotic cells were defined as Caspase-3− ve/RIP3high + ve, early or 
late apoptotic (Caspase-3+ ve/RIP3− ve), RIP1-dependent apoptotic 
(RIP1-APO, Caspase-3+ ve/RIP3+ ve) and Double Negative (DN, Cas-
pase-3− ve/RIP3− ve) (b, c). Then each of these live and dead cell popu-
lations were then gated on a H2AX vs. PARP dot-plots to show the 
incidence of DDR  (H2AX+ ve/PARP− ve), hyper-activation of PARP 
 (H2AX+ ve/PARP+ ve), parthanatos  (H2AX− ve/PARP+ ve) and QN 
 (H2AX− ve/PARP− ve), (d, e)
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Likewise for autophagy  (LC3B+ ve) and ER stress 
 (PERK+ ve) were phenotyped then  LC3B+ ve/PERK− ve (live 
and dead cells) were analysed for RIP3/Caspase-3 to deter-
mine the incidence of resting/necroptosis, early or late apop-
tosis, RIP1-dependent apoptosis and DN phenotypes. Live 
and dead autophagic cells were also phenotyped for H2AX 
and PARP to determined levels of DDR, H2AX hyper-acti-
vation of PARP and parthanatos (Fig. 6).
Statistical analysis
All experiments n = 3, with results expressed as mean ± SEM 
for percentage positive or Median Fluorescent Intensity 
(MFI). Student t tests were performed in GraphPad soft-
ware Inc., USA with P ≥ 0.05 not considered significant 
(NS), P ≤ 0.05*, P ≤ 0.01** ,  P < 0.001*** when treated 
cells were compared to untreated.
Results
Induction of apoptosis and necroptosis
Shikonin induced a high degree of early (57%, Caspase-3+ ve/
Zombie  NIR− ve) and late apoptosis (16%, Caspase-3+ ve/
Zombie  NIR+ ve) compared to untreated Jurkat cells (Fig. 2a, 
b) [24]. Live cells showed necroptosis  (RIP3high + ve/Cas-
pase-3− ve), with an up-regulation of RIP3 (28%, Median 
Fluorescent Intensity MFI 50,148 ± 2291), early apoptosis 
 (RIP3− ve/Caspase-3+ ve, 56%) and RIP1-dependent apop-
tosis  (RIP3+ ve/Caspase-3+ ve, 17%) compared to untreated 
cells (Fig. 3a, c) [23, 26]. Dead shikonin treated cells like 
untreated showed only a high degree of late apoptosis 
(Fig. 3b, d) [23].
All live treated (except early apoptotic) populations 
showed increased hyper-activation of PARP (DP,  H2AX+ ve/
PARP+ ve) and parthanatos  (H2AX− ve/PARP+ ve) with a 
decreased incidence of the quadruple negative population 
for all live cell phenotypes compared to untreated cells (QN, 
Fig. 4a, b, Fig. 1S i–l). While the two live apoptotic popula-
tions showed a decrease in DDR (Fig. 4c, Fig. 1Si, j). All 
dead cell phenotypes also showed an increase hyper-acti-
vation of PARP  (H2AX+ ve/PARP+ ve) and a decrease in the 
incidence of the QN populations compared to untreated dead 
cells (Fig. 4a, Fig. 1Sm–p). Dead cell parthanatos (unlike 
live cells) was decreased in both dead apoptosis populations 
but like live cells this was increased in the necroptotic and 
DN populations (Fig. 4b, Fig. 1Sm–p). The late apoptotic 
population however, also showed an increase in DDR, while 
this was decreased in the necroptotic and RIP1-dependent 
apoptotic cells compared to untreated dead cells (Fig. 4c, 
Fig. 1Sm–o).
zVAD blockade of apoptosis
Pre-treatment of cells with pan-caspase blocker zVAD (20 
µM) before shikonin reduced the incidence of early and late 
apoptosis but increased necrosis (Caspase-3− ve/Zombie 
 NIR+ ve, Fig. 2b, c) [23]. Blockade of shikonin with zVAD 
increased the incidence of necroptosis compared to treated 
cells (Fig. 3e). RIP1-dependent apoptosis was reduced while 
the DN population increased compared to shikonin treat-
ment (Fig. 3a, c, e). Dead cells also showed a decrease in 
late apoptosis and an increase in DN population compared 
to drug treatment (Fig. 3b, d, f).
The blockade of shikonin with zVAD showed no change 
in HA2X hyper-activation of PARP in all live cell pheno-
types compared to drug treatment, with the exception of a 
reduction in the QN population (Fig. 4a, Fig. 2Sa–d). While 
most live cell phenotypes showed increased parthanatos 
(Fig. 4b, Figs. 1Sb–d, 2Sb–d), early apoptotic cells showed 
no change compared to drug alone or untreated cells (Fig. 4, 
Figs. 1Sa, i, 2Sa). In contrast DDR was only increased in the 
RIP1-dependent apoptotic cells compared to treated cells 
(Fig. 4c, Figs. 1Sb, j, 2Sb). All the dead phenotypes after 
zVAD blockade now showed reduced hyper-action of PARP 
compared to drug alone (Fig. 4a, Figs. 1Sm–p, 2Se–h). 
Parthanatos and DDR was unchanged after zVAD block-
ade in the all phenotypes (except DN) compared to drug or 
untreated cells respectively (Fig. 4b, c, Figs. 1Se–g, m–o, 
2Se–g). However, the dead DN population showed increased 
parthanatos after zVAD blockade of shikonin compared to 
drug or untreated cells (Fig. 4b, Figs. 1Sh, p, 2Sh).
Necrostatin‑1 blockade of necroptosis
Necrostatin-1 is known to inhibit necroptosis [23, 27], 
interestingly more necrosis (15%) was detected along with 
early apoptotic cells compared to drug alone (Fig. 2d). The 
up-regulation of RIP3 (MFI 31,339, NS) was blocked by 
necrostatin-1 while the incidence of the necroptotic pheno-
type was increased (33% compared to 6% shikonin, Fig. 3c, 
g) [23, 27]. Live early apoptosis was also reduced (43%) 
while the level of RIP1-dependent apoptosis was maintained 
(13%, Fig. 3c, g). Such dead cells showed a reduction in late 
apoptosis in combination with a rise in the DN population 
(Fig. 3d, f, h).
Further analysis of necrostatin-1-shikonin treated live 
cells showed that hyper-activation of PARP was increased 
in the early apoptotic, RIP1-dependent apoptotic and DN 
populations compared to untreated cells (Fig. 4a, Figs. 1Si, 
j, l, 2Si, j, l). The blocked necroptotic phenotype and 
RIP1-dependent apoptotic cells had increased parthana-
tos but less DDR and via versa for the DN cells compared 
to untreated cells (Fig. 4b, c, Figs. 1Sa–d, 2Si–l). The 
incidence of QN was decreased in the RIP1-dependent 
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Fig. 2  Cell death and caspase-3 activation assay. Jurkat cells were 
untreated (a), treated with 0.5 µM shikonin for 24 h (b), pre-treated 
with 20 µM zVAD for 2 h then with 0.5 µM shikonin for 24 h (c), 
pre-treated with 60 µM necrostatin-1 (Nec-1) for 2  h then with 0.5 
µM shikonin for 24 h (d), pre-treated with 20 µM zVAD and 60 µM 
necrostatin-1 (Nec-1) for 2 h then with 0.5 µM shikonin for 24 h (e), 
treated with 100 µM CQ for 24 h (f), pre-treated with 20 µM zVAD 
for 2 h then with 100 µM CQ for 24 h (g). n = 3, student t test NS (not 
significant), P < 0.05*, P < 0.01**, P < 0.001***, with arrows indicat-
ing change compared to untreated cells
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apoptotic and DN populations compared to untreated cells 
(Figs. 2Sj, l, 1Sb, d). Analysis of dead cells showed that 
late apoptotic and blocked necroptotic phenotypes had 
increased hyper-activation of PARP compared to untreated 
cells (Fig. 4a, Figs. 2S, m, o, 1Se, g). The dead RIP1-
dependent apoptotic cells showed no change in hyper-
activation of PARP parthanatos and DDR compared to 
untreated controls (Fig. 4a, b, c, Figs. 2Sn, 1Sf). The late 
apoptotic and DN cells showed a decreased incidence of 
parthanatos with increased DDR compared to untreated 
cells (Fig. 4b, c, Fig. 2Sm, p).
Blockade of apoptosis and necroptosis
Dual blockade of shikonin with zVAD and necrostatin-1 
was investigated and the degree of early apoptosis was 
similar to that observed with zVAD blockade with a low 
level of cell death (Fig. 2e). Live and early apoptotic cells 
Fig. 3  RIP3 and caspase-3 activation assay. After gating on live 
and dead cells from a Zombie NIR vs. Caspase-3-BV650 dot-plot 
untreated live (a) and dead (b) Jurkat cells were analysed on a RIP3-
PE vs. Caspase-3-BV650 dot-plot with resting or necroptotic pheno-
type indicated by  RIP3high + ve/Caspase-3− ve with the RIP3 Median 
Fluorescent Intensity (MFI) up-regulated during necroptosis. The 
apoptosis phenotype  (RIP3− ve/Caspase-3+ ve), RIP1-dependent apop-
tosis  (RIP3+ ve/Caspase-3+ ve) and double negative  (RIP3− ve/Cas-
pase-3− ve). Live and dead cells treated with 0.5 µM shikonin for 24 h 
(c, d) pre-treated with 20 µM zVAD for 2  h then with 0.5 µM shi-
konin for 24 h (e, f) pre-treated with 60 µM Nec-1 for 2 h then with 
0.5 µM shikonin for 24 h (g, h) pre-treated with 20 µM zVAD and 60 
µM Nec-1 for 2 h then with 0.5 µM shikonin for 24 h (i, j) n = 3, stu-
dent t test NS (not significant), P < 0.05*, P < 0.01**, P < 0.001***, 
with arrows indicating change compared to untreated cells
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showed a high percentage of cells with RIP3 alone (33%) 
with reduced expression of RIP3 indicating that necroptosis 
was blocked (MFI 24,765, NS, Fig. 3i). Early apoptosis and 
RIP1-dependent apoptosis was low (11%, Fig. 3i). The inci-
dence of the live DN population was enhanced as observed 
with zVAD and necrostatin-1 blockade (Fig. 3c, e, g, i). Such 
dead cells showed an increased presence of RIP1-dependent 
apoptosis and a similar level of late apoptosis compared to 
zVAD-shikonin treated cells (Fig. 3j).
The RIP1-dependent apoptotic and blocked necroptotic 
cells after dual blockade of shikonin both showed increased 
levels of hyper-activation of PARP and parthanatos with a 
reduction in DDR (Fig. 4a, b, Fig. 2Sr, s). While the early 
apoptotic and DN phenotypes now showed no change in the 
incidence of these populations compared to untreated cells 
(Fig. 4a, b, Fig. 2S, q, t). Such analysis of the late apoptotic 
population had more DDR but less parthanatos, while RIP1-
dependent apoptotic cells showed no change compared to 
untreated cells (Fig. 4 b, c, Fig. 2Su, v). The blocked dead 
necroptotic phenotype had reduced levels of hyper-activation 
of PARP, parthanatos and DDR which was now increased 
(for hyper-activation of PARP) in the DN phenotype com-
pared to untreated cells (Fig. 4a, b, c, Fig. 2Sw, x).
Initiation of autophagy
Treatment with a lysosome-autophagosome fusion inhibitor 
such as chloroquine (CQ) to initiate autophagy resulted in a 
small increase in late apoptosis compared to untreated cells 
(Fig. 2f). Increased LC3B expression above untreated cells 
was detected (30%) in live cells with no ER stress (PERK) 
and low levels of LC3B in dead cells (similar to untreated 
cells, Fig. 5a–d) [20, 21]. Gating on live  LC3B+ ve/PERK− ve 
cells showed lower levels of RIP1-dependent apoptosis 
and early apoptosis than untreated cells (Fig. 6a, e). Dead 
autophagic cells showed a twofold increase in the resting 
cell phenotype  (RIP3+ ve/Caspase-3− ve, 34%, Fig. 6c, g). 
The incidence of late apoptosis and the DN populations was 
reduced (Fig. 6c, g).
Further analysis of H2AX and PARP after initiation of 
autophagy showed significantly less DDR and parthanatos 
in live autophagic cells, with the QN population significantly 
increased compared to untreated autophagic cells (Fig. 6b, 
f). Whilst dead CQ treated cells had significantly more DDR, 
less parthanatos and a lower incidence of the QN population 
than that observed in untreated autophagic cells (Fig. 6d, h).
Blocking by zVAD
Blockade of apoptosis by zVAD during initiation of 
autophagy resulted in a small increase in necrosis (Fig. 2g). 
LC3B expression increased in live (53%) and dead after 
zVAD blockade (25%) cells with no ER stress compared 
to autophagic cells (Fig. 5e, f) [20, 29]. Gating on live 
 LC3B+ ve/PERK− ve cells showed the same low levels of 
RIP1-dependent apoptosis and early apoptosis observed 
with CQ (Fig. 6a, e, i). Dead autophagic cells treated with 
zVAD-CQ had a lower incidence of the resting or necrop-
totic phenotype (20%) compared to that observed in dead 
autophagic cells (Fig. 6c, g, k). Whilst the incidence of dead 
late apoptosis and RIP1-dependent apoptosis showed little 
change compared to autophagy alone despite blockade by 
zVAD (Fig. 6g, k). The incidence of the dead DN population 
was increased compared to that observed during autophagy 
(Fig. 6c, g, k).
Further analysis of live cell DDR and parthanatos showed 
a fall in parthanatos and increased DDR after initiation of 
autophagy with zVAD blockade compared to autophagic 
cells (Fig. 6b, f, j). Dead autophagic cells treated with 
zVAD-CQ had significantly less DDR  (H2AX+ ve/PARP− ve) 
than autophagic cells (P < 0.001, as indicated by the black 
arrow) as well as a lower level of hyper-activated PARP 
(Fig. 6h, l).
Discussion
The intracellular labelling of cells with fluorescently tagged 
antibodies to RCD defining target molecules, active cas-
pase-3 (apoptosis), up-regulated RIP3 (necroptosis), up-
regulated LC3B (autophagy), PARP (parthanatos), H2AX 
(DDR), PERK (ER Stress) in conjunction with a fixable 
live-dead cell stain gives the researcher detailed informa-
tion about the distribution and incidence of multiple forms 
of RCD in live and dead cells simultaneously. This a major 
advance upon the information gained by other methodolo-
gies where there is no such discrimination [6–8, 16, 19–21, 
23].
The use of a live-dead fixable stain with an active cas-
pase-3 antibody allows the identification of early (Cas-
pase-3+ ve/Viability− ve), late apoptosis (Caspase-3+ ve/Via-
bility+ ve) and necrosis (Caspase-3− ve/Viability+ ve) [19, 23]. 
These populations were all observed after 24 h treatment 
with shikonin which is known to induce both apoptosis and 
necroptosis in Jurkat cells. So the addition of RIP3 permit-
ted the identification of necroptosis by the up-regulation of 
RIP3 by shikonin above control levels in caspase-3 negative 
live cells. An increased incidence of live RIP1-dependent 
apoptosis was also detected and defined as positive for RIP3 
and caspase-3 assuming that RIP1 which by definition is also 
present with RIP3 [6, 12–14, 19, 23]. Early and late apop-
tosis was also detected and defined not only by the presence 
of active caspase-3 but also the absence of RIP3 in the live 
and dead cells.
After zVAD blockade of shikonin induced apoptosis 
which resulted in an increase in necrotic cell death [19, 
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23], live cells showed an increased incidence of necroptosis 
coupled with an increase in the DN population compared 
to shikonin treatment. While dead cells showed a shift to 
the DN phenotype and away from that of apoptosis indicat-
ing that shikonin was still initiating apoptosis while zVAD 
was blocking the activation of caspase-3. Necrostatin-1 pre-
treatment with shikonin resulted in no up-regulation of RIP3 
indicating a blockade of necroptosis [19, 23, 27]. Blockade 
of necroptosis resulted in increased incidence of this popula-
tion with a correspondingly lower level of early apoptosis 
than was expected. Shikonin with zVAD and necrostatin-1 
blockade showed lower levels of early and late apoptosis 
with an increase in the incidence of blocked necroptotic cells 
which again displayed no up-regulation of RIP3. However, 
zVAD did not block dead cell RIP1-dependent apoptosis 
indicating that zVAD did not fully block the activation of 
caspase-3 via this signalling pathway in the presence of 
necrostatin-1.
Further discernible differences in the four live and dead 
RCD phenotypes were detected by the addition of PARP and 
H2AX antibodies allowing the researcher to distinguish a 
further 32 subpopulations of cells by measurement of DDR, 
parthanatos, hyper-activation of PARP and a QN population 
[7, 8]. Shikonin treatment increased parthanatos and H2AX 
hyper-activation of PARP in all live cell RCD phenotypes 
except early apoptotic cells. Dead cell RCD phenotypes also 
showed increased H2AX hyper-activation of PARP, while 
both apoptotic populations showed a decrease in parthanatos 
while other phenotypes showed an increase. Dead cell levels 
of DDR were increased by shikonin in late apoptotic cells 
but decreased in other phenotypes.
The zVAD blockade of shikonin resulted in no change 
in these levels of hyper-activation (except DN) and DDR 
(increased in RIP1-dependent apoptosis) in all live cell phe-
notypes, with mainly high levels of parthanatos observed 
in these populations. While the dead cell phenotypes after 
zVAD blockade of shikonin showed reduced levels of hyper-
activation and parthanatos with no change in DDR levels, 
except increased DDR levels in both types of apoptosis. In 
contrast necrostatin-1 blockade of shikonin reduced levels 
of live cell hyper-activation of PARP in the live blocked 
necroptotic phenotype and increased levels in early apop-
totic and DN cells compared to drug treatment. Parthanatos 
and DDR was reduced except were DDR was increased in 
live RIP1-dependent apoptosis and DN phenotypes com-
pared to drug treatment. While hyper-activation of PARP 
was reduced in dead RIP1-dependent apoptosis and DN 
phenotypes there was no change observed in others after 
necrostatin-1 blockade of shikonin. In contrast dead cell 
parthanatos was unchanged while DDR levels increased in 
all dead cell phenotypes compared to drug treatment. Dual 
blockade of shikonin with zVAD and necrostatin-1 showed 
reductions of H2AX hyper-activation of PARP in all live 
and dead cell phenotypes and so almost cancelled out the 
effect of shikonin induced cell damage. This was also true 
of the levels of parthanatos observed in all dead cells and 
live early apoptosis and DN phenotypes, while an increase in 
parthanatos was observed in live RIP1-dependent apoptosis 
and the blocked necroptotic phenotype. While live cell DDR 
was reduced and unchanged in dead cell phenotypes. Thus it 
is possible by the use of this novel intracellular labelling of 
target antigen specific for each RCD of interest to show the 
mode of action of drugs and the mechanisms involved with 
blocking agents such as zVAD and necrostatin-1.
Autophagic treatment ± zVAD showed increased necrosis, 
late apoptosis and initiation of autophagy respectively [29]. 
Analysis of LC3B expressing live cells showed a decrease 
in both types of apoptosis, while after zVAD pre-treatment 
a decrease in early apoptotic cells was observed. Increased 
levels of DDR and parthanatos resulting in hyper-activation 
of PARP and thus  NAD+ depletion with resultant autophagic 
and necrotic cell death have been previously reported [28]. 
Thus it is interesting to show in this study that live high 
LC3B expressing Jurkat cells displayed reduced levels of 
DDR and parthanatos indicating that the autophagic process 
enhanced cell health while zVAD reduced this affect [28]. 
However, dead autophagic cells showed an enhanced level 
of DDR with reduced levels of parthanatos while zVAD 
reduced the enhancement of DDR in dead cells. Thus the 
assay here showed a DDR related mechanism of the protec-
tive affect that autophagy has upon cells within live cells 
with resultant increase in dead cells.
This new approach for the measurement of cell death 
reveals the complexity of RCD by identifying 124 popu-
lations in live and dead cells and the complex shifts after 
blockade of shikonin by zVAD and necrostatin-1 in the inci-
dence of defined RCD phenotypes of necroptosis, apoptosis 
and RIP1-dependent apoptosis in terms of DDR, parthanatos 
and hyper-activation of PARP revealing also the protective 
effects of autophagy on cell health via DNA repair. To our 
knowledge, this is the most comprehensive method for the 
investigation of cell death and as such it carries potential 
to expand detailed studies of cell death across both basic 
research and clinical settings.
Fig. 4  Hyper-activation of PARP, parthanatos and DDR assay. Jurkat 
untreated, treated with 0.5 µM shikonin or pre-treated zVAD (20 µM) 
and or Necrostatin-1 (60 µM) for 2 h then incubated with 0.5 µM shi-
konin for 24  h. After gating on live and dead cells from a Zombie 
NIR vs. Caspase-3-BV650 dot-plot untreated or treated live and dead 
Jurkat cells were analysed on a RIP3-PE v Caspase-3-BV650 dot-
plot. From which early and late apoptotic, necroptotic/resting, RIP1-
dependent apoptotic and double negative (DN) populations were ana-
lysed for H2AX and PARP, see Figs. 1S, 2S for detailed information. 
The incidence of hyper-activation of PARP (a), parthanatos (b) and 
DDR (c) were determined for all populations listed above. n = 3, stu-
dent t test NS (not significant), P < 0.05*, P < 0.01**, P < 0.001*** 
compared to untreated cells
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Fig. 5  Autophagy assay. 
Untreated Jurkat cells or after 
CQ ± zVAD treatment for 24 h 
were analysed by gating on live 
and dead cells from a Zombie 
NIR vs. Caspase-3-BV650 
dot-plot with live and dead 
of untreated cells (a, b), CQ 
treated (c, d) or CQ + zVAD 
treated Jurkat cells (e, f) were 
then analysed for autophagy 
 (PERK− ve/LC3B+ ve) and ER 
stress  (PERK+ ve/LC3B− ve) 
from a LC3B v PERK do-plot. 
n = 3, student t test NS (not sig-
nificant), P < 0.05*, P < 0.01**, 
P < 0.001***, with arrows 
indicating change compared to 
untreated cells
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